Six different gram-negative bacilli were serially transferred through subinhibitory concentrations of seven quinolone derivatives or related organic acids. A gradual, stepwise decrease in susceptibility was noted with all seven drugs, and the resistant cultures demonstrated a concomitant cross-resistance to the other drugs.
In the present report, we describe nearly complete crossresistance among three new agents, ciprofloxacin, DJ-6783, and enoxacin, as well as cinoxacin, nalidixic acid, norfloxacin, and oxolinic acid. Seven different clinical isolates were tested by serial transfers through broth containing separate subinhibitory concentrations of each drug. In the first experiment, standardized microdilution susceptibility tests (7) were used to determine MICs for the last six drugs listed.
The trays were inoculated with about 5 x 105 CFU/ml, and
MICs were recorded after 16 to 18 h at 35°C. All of the broth (0.1 ml) in those wells that contained the highest concentration with visible growth was transferred to 5 ml of Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) After 5 to 8 h of incubation, the broth subcultures were adjusted to match the turbidity of a McFarland 0.5 standard. That adjusted suspension was then used to inoculate another microdilution panel, and the whole process was repeated for 7 consecutive days. In the first experiment, serial passage through each of six study drugs (excluding ciprofloxacin) was accomplished, and then MICs for the five other drugs were determined. Ciprofloxacin was tested in a second * Corresponding author. experiment, and thus ciprofloxacin MICs were not determined after passage through the other compounds, but concomitant resistance to all seven drugs was documented. Table 1 describes the result of these experiments. All seven drugs demonstrated a stepwise increase in MICs of the drug that the cultures were being passed through. At the same time, MICs for the other drugs were concomitantly increased. With all six gram-negative bacilli, development of resistance and concomitant cross-resistance was demonstrated. Norfloxacin MICs > 16 ,ug/ml were obtained only with Klebsiella pneumoniae, and MICs 2 8.0 jxg/ml were obtained with both Enterobacter cloacae strains and with one strain of P. aeruginosa. Enoxacin MICs 2 8.0 ,ug/ml were obtained with all three Enterobacter strains and one of the P. aeruginosa strains. DJ-6783 MICs 2 8.0 ,ug/ml were obtained with all six isolates. Ciprofloxacin MICs never exceeded 1.0 ,ug/ml, but 32-fold increases were seen. Resistance to DJ-6783, enoxacin, or norfloxacin could be developed by passage through nalidixic acid or cinoxacin.
Our observations with norfloxacin confirm and expand the results reported by Tenney et al. (12) . These investigators utilized an agar dilution technique with an inoculum significantly greater than that used in our broth dilution testing system. Chin and Neu (1) determined that the frequency of resistant variants for enoxacin and norfloxacin was generally <10-9 within different cultures. Consequently, a very heavy inoculum would be needed to reliably select resistant cells within a population. With a lighter inoculum, random selection could require several passages before resistant cells were detected. Even with a lighter inoculum of ca. 5 x 104 CFU per microdilution well (5 x 105 CFU/ml), we were able to observe a gradual stepwise increase in MICs for all seven quinolone derivatives or organic acids. Serial transfers through subinhibitory concentrations of ciprofloxacin, DJ-6783, enoxacin, or norfloxacin did result in increased MICs, but multiple transfers were required. Cinoxacin and nalidixic acid developed resistance more rapidly. The rate of resistance development cannot be measured quantitatively with the methods used in this study.
In our studies, resistance to the newer quinolone derivatives was rarely of obvious clinical significance; presumably, higher levels of resistance could have been achieved if other laboratory methods had been utilized (1) . Since ciprofloxacin is intended for systemic therapy, moderate increases in MICs may be much more significant, because lower concentrations could be achieved at the site of infection compared with levels obtained in the urinary tract. Crump et al. (2) observed peak serum levels of 2.4 ,g/ml after dosage with a ANTIMICROB. AGENTS CHEMOTHER. 500-mg ciprofloxacin tablet, and the serum half-life was 3.9 h. Consequently, 5 to 6 h after dosing, the serum level may be below 1.0 ,ug/ml. They also determined that 57% of the drug in the serum penetrated into blister fluid. Consequently, the concentration at the site of infection could very well be below 1.0 ,g/ml, which approaches the maximal MIC that we observed with P. aeruginosa. Enoxacin has similar pharmacokinetic properties, but higher serum levels can be achieved. Chin and Neu (1) expect serum levels in excess of 4.0 P,g/ml for 6 to 8 h after dosing. After our strains were exposed to enoxacin, we observed MICs as high as 32 pug/ml, and that could be clinically significant. Our primary goal was to evaluate cross-resistance between the quinolone derivatives and related organic acids. Jones and Barry (5) demonstrated that Enterobacteriaceae with elevated MICs for cinoxacin, nalidixic acid, or oxolinic acid tended to be less susceptible to norfloxacin. Fass (3) observed a similar relationship between ciprofloxacin and norfloxacin. In the current study, we observed that resistance to one compound can be developed by serial transfers through subinhibitory concentrations of a different quinolone derivative or related organic acid. Presumably, the mechanism responsible for development of resistance affects all of the compounds that we have studied, although with the newer, more potent quinolone derivations, significant levels of resistance develop much more slowly. The mechanism of resistance may be analogous to that which has been defined for nalidixic acid, i.e., a change in the configuration of bacterial DNA gyrase (4).
Extremely high MICs for cinoxacin and nalidixic acid are obtained after a few serial transfers through subinhibitory concentrations of either drug (6, 10, 12) . Clinically significant resistance does occur during therapy with either drug (6, 10) . Our data indicate that selection of resistant populations by widespread use of cinoxacin or nalidixic acid might seriously diminish the efficacy of the newer quinolone derivatives, especially those intended for systemic therapy.
